Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness

Hepatology

Volumn 41, Issue 6, 2005, Pages 1383-1390

  Godkin, Andrew ^a,b   Davenport, Miles ^a   Hill, Adrian V S ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CORE PROTEIN; EPITOPE; GLYCOPROTEIN; HEPATITIS B VACCINE; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR13 ANTIGEN; HLA DR3 ANTIGEN; HLA DR7 ANTIGEN; LIGAND; MEMBRANE ANTIGEN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HLA TYPING; IC 50; IMMUNE RESPONSE; INFECTION SENSITIVITY; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE;

BINDING, COMPETITIVE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; DRUG RESISTANCE, VIRAL; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS II; LIGANDS; PEPTIDE FRAGMENTS; VIRAL CORE PROTEINS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 20144375709     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20716     Document Type: Article

References (34)

1. Sherlock S. Clinical features of hepatitis. In: Zuckerman A, Thomas H, eds. Viral Hepatitis. Edinburgh: Churchill Livingstone, 1993:1-20.
2. Dienstag J, Werner B, Polk P. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficiency. Ann Intern Med 1984;101:34-40.
3. Kalams S, Walker B. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-2204.
4. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990;145:3442-3449.
5. Nayersina R, Fowler P, Missale G, Missale G, Cerny A, Schlicht HJ, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993;10:4659-4671.
6. Chisari F, Ferrari C. Hepatitis B virus pathogenesis. Annu Rev Immunol 1995;13:29-60.
7. Rammensee H-G. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995;7:85-96.
8. Davenport M, Hill A. Peptides associated with MHC class I and II molecules. In: Browning MA, ed. HLA/MHC: Genes, Molecules and Function. Oxford: Bios Scientific Publications, 1996:277-308.
9. Trowsdale J. MHC. Res Immunol 1997;148:425-426.
10. Hill A. The immunogenetics of human infectious diseases. Annu Rev Immunol 1998;16:593-617.
11. Hill A, Elvin J, Willis A, Aidoo M, Allsopp CE, Gotch FM, et al. Molecular analysis of the association of HLA-B53 and resisitance to severe malaria. Nature 1992;360:434-439.
12. Thursz M, Thomas H, Greenwood B, Hill A. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997;17:11-12.
13. Diepolder H, Jung M-C, Keller K, Schraut W, Gerlach JT, Gruner N, et al. A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin Exp Immunol 1998;113:244-251.
14. Thurz M, Kwiatkowski D, Allsop C, Greenwood B, Thomas H, Hill A. Association between an MHC allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995;332:1065-1069.
15. Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997;26:503-507.
16. Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002;360:991-995.
17. Alper C, Kruskall M, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989;321:708-712.
18. Robbins P, Evans E, Ding A, Warner N, Brodsky F. Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes. Hum Immunol 1987;18:301-313.
19. Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, et al. Identification of immunodominant T-cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991;88:214-222.
20. Honorati M, Dolzani P, Mariani E, Piacentini A, Lisignoli G, Ferrari C, et al. Epitope specificity of Th0/Th2 CD4+ T-lymphocyteclones induced by vaccination with rHBsAg vaccine. Gastroenterology 1997;112:2017-2027.
21. Celis E, Ou D, Otvos L. Recognition of hepatitis B surface antigen by human T lymphocytes: proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J Immunol 1988; 140:1808-1815.
22. Milich D. Immune response to hepatitis B virus proteins: relevance of the murine model. Semin Liver Dis 1991;11:93-112.
23. Milich D, Thornton G, Neurath A, Kent S, Michel M-LTP, Chisari F. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985;228:1195-1199.
24. Doherty P, Zinkernagel R. A biological role for the majorhistocompatability antigens. Lancet 1975;1:1406-1409.
25. Sercarz E, Lehmann P, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993;11:729-766.
26. Ghosh P, Amaya M, Mellins E, Wiley D. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995; 378:457-462.
27. Smith K, Pyrdol J, Gauthier L, Wiley D, Wucherpfennig K. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med 1998;188:1511-1520.
28. Stern L, Brown J, Jardetzky T, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-221.
29. Hammer J, Belunis C, Bolin D, Papadopoulos J, Walsky R, Higelin J, et al. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc Natl Acad Sci USA 1994;91:4456-4460.
30. Geluk A, Van Meijgaarden KE, Janson AA, Drijfhout JW, Meloen RH, De Vries RR, et al. Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. J Immunol 1992;149:2864-2871.
31. Godkin A, Friede T, Davenport M, Stevanovic S, Willis A, Jewell D, et al. Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependant diabetes susceptibility allele HLA-DQ8 (DQ 3.2). Int Immunol 1997;9:905-911.
32. Craven D, Awdeh Z, Kunches L, Yunis EJ, Dienstag JL, Werner BG, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986;105:356-360.
33. McDermott A, Zuckerman J, Sabin C, Marsh S, Madrigal J. Contribution of human leukocyte antigens to antibody response to hepatitis B vaccination. Tissue Antigens 1997;50:8-14.
34. Milich D, Hughes J, McLachlan A, Langley K, Thornton G, Jones J. Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. J Immunol 1990;9:3535-3543.